Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

HYPAQUE - CYSTO

&times

Overview

What is HYPAQUE - CYSTO?

HYPAQUE-CYSTO, brand of diatrizoate meglumine, is a water-soluble radiopaque diagnostic medium. It is a triiodinated benzoic acid derivative. It is constituted as a radiopaque iodinated anion (diatrizoate) and a radiolucent cation (meglumine). It is a colorless, microcrystalline solid which is readily soluble in water.

HYPAQUE-CYSTO is a sterile aqueous solution containing 30 g (w/v) of the meglumine salt of diatrizoic acid per 100 mL aqueous solution. The sterile solution is clear and colorless to pale yellow. The pH is adjusted between 6.5 and 7.7 with hydrochloric acid, or diatrizoic acid, or meglumine. It does not contain an antibacterial preservative. It is relatively thermostable and may be autoclaved. Edetate calcium disodium 1:10,000 has been added as a sequestering stabilizing agent. Each 1 mL contains approximately 141 mg of organically bound iodine.

It has an osmolality of 633 mosm/kg (determined by VPO) and is hypertonic to blood.

The viscosity of the solution is 1.94 cp at 25°C and 1.42 cp at 37°C.

HYPAQUE-CYSTO is a 30 percent solution of 1-Deoxy-l (methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (CHINO • CHNO) with a molecular weight of 809.13, and has the following structural formula:



What does HYPAQUE - CYSTO look like?



What are the available doses of HYPAQUE - CYSTO?

Sorry No records found.

What should I talk to my health care provider before I take HYPAQUE - CYSTO?

Sorry No records found

How should I use HYPAQUE - CYSTO?

HYPAQUE-CYSTO is indicated for retrograde cystourethrography in adult and pediatric patients.

After the bladder is emptied, HYPAQUE-CYSTO is gently instilled without force, often beyond the first desire to micturate, but not beyond the point of urgency or mild discomfort. The volume required to fill the bladder to slightly less than capacity may vary from patient to patient.

Bladder capacity in normal adults is generally 200 mL to 300 mL, and rarely, up to 600 mL. Capacity at birth is 20 mL to 50 mL, and increases about 400 percent in the first year. In children 3 to 5 years old, bladder capacity is 150 mL to 180 mL. In children older than 8 years, it is in the low adult range.

In disease, bladder capacity in adults may vary from 50 mL in a hypertonic reflex bladder to over 1000 mL in an atonic or sensory paralytic bladder or chronic lower urinary tract obstruction.

Repeat examination may be required to detect reflux, or in function studies.

The concentration varies with technique and equipment used. HYPAQUE-CYSTO may be diluted with sterile water or 5 percent dextrose solution, as indicated in the following table. A 10 percent solution is isotonic.

Note: To achieve the following concentrations some of the contrast agent must be removed prior to dilution

Dilution and withdrawal of the contrast agent should be accomplished under aseptic conditions with sterile syringes. The solution should be inspected visually for particulate matter and discoloration prior to administration.


What interacts with HYPAQUE - CYSTO?

HYPAQUE-CYSTO has no absolute contraindication in its recommended use.



What are the warnings of HYPAQUE - CYSTO?

SEVERE ADVERSE EVENTS—INADVERTENT INTRATHECAL USE

Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not administered intrathecally.

Ionic iodinated contrast media inhibit blood coagulation, , more than nonionic contrast media. Nonetheless, it is prudent to avoid prolonged contact of blood with syringes containing ionic contrast media.

Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Numerous factors, including length of procedure, catheter and syringe material, underlying disease state and concomitant medications may contribute to the development of thromboembolic events. For these reasons, meticulous angiographic techniques are recommended including close attention to guidewire and catheter manipulation, use of manifold systems and/or three-way stopcocks, frequent catheter flushing with heparinized saline solutions and minimizing the length of the procedure. The use of plastic syringe in place of glass syringes has been reported to decrease but not eliminate the likelihood of clotting.

Serious or fatal reactions have been associated with the vascular entry of radiopaque media. It is important that a course of action be carefully planned in advance for the treatment of possible serious reactions.


What are the precautions of HYPAQUE - CYSTO?

General

Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for the management of any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. Competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions have occurred (See ).

The possibility of a reaction, including serious, life-threatening, fatal, anaphylatic or cardiovascular reactions should always be considered (see ). It is of utmost importance that a course of action be carefully planned in advance for immediate treatment of serious reactions, and that adequate and appropriate personnel be readily available in case of any reaction.

Before injecting a contrast medium, the patient should be questioned for a history of allergy. A positive history does not arbitrarily contraindicate the use of a contrast agent where a diagnostic procedure is considered essential, but caution should be exercised (see ).

The possibility of an idiosyncratic reaction in susceptible patients should always be considered (see ). The susceptible population includes patients with a history of a previous reaction to a contrast media, patients with a known sensitivity to iodine per se, and patients with known clinical hypersensitivity (ie, bronchial asthma, hay fever, and food allergies).

Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions in such patients should be considered. Recent reports indicate that such pretreatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.

The occurrence of severe idiosyncratic reactions has prompted the use of several pretesting methods. However, pretesting cannot be relied upon to predict severe reactions and may itself be hazardous for the patient. It is suggested that a thorough medical history with emphasis on allergy and hypersensitivity, prior to the injection of any contrast media, may be more accurate than pretesting in predicting adverse reactions.

Information for Patients





      Patients receiving injectable radiopaque diagnostic agents should be instructed to:

      Drug/Laboratory Test Interactions

      Under certain circumstances (pH, temperature, concentrations, time), diatrizoate solutions are incompatible with promethazine hydrochloride, diphenhydramine hydrochloride, brompheniramine maleate, or papaverine hydrochloride solutions.

      BENADRYL, brand of diphenhydramine hydrochloride, may cause precipitation when mixed in the same syringe with HYPAQUE-CYSTO.

      Although interference with these laboratory tests have not been reported following cystography absorption (from the bladder or by pyelorenal back flow), they have occurred following direct injection.

      Diatrizoate salts interfere with several laboratory urine and blood tests.

      Coagulation:

      Platelet aggregation:

      Serum calcium:

      Red cell counts:

      Leukocyte counts:

      Urea nitrogen (BUN):

      Serum creatinine:

      Urine osmolarity and specific gravity. Decreased due to induced diuresis.

      Urine cultures. Diatrizoate in urine cultures may inhibit bacterial growth.

      Protein-bound iodine (PBI) and total serum organic iodine:

      3

      Carcinogenesis, Mutagenesis, Impairment of Fertility

      Long-term studies in animals have not been performed in order to evaluate carcinogenic potential, mutagenesis, or whether HYPAQUE-CYSTO can affect fertility in males or females.

      Pregnancy Category C

      Animal reproduction studies have not been conducted with diatrizoate meglumine. It is also not known whether it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, diatrizoate meglumine should be given to a pregnant woman only if clearly needed.

      Labor and Delivery

      It is not known whether use of these contrast agents during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

      Nursing Mothers

      Diatrizoate salts are excreted unchanged in human milk. Because of the potential adverse reactions, although it has not been established that serious adverse reactions occur in nursing infants, caution should be exercised when these contrast media are administered to a nursing woman.


      What are the side effects of HYPAQUE - CYSTO?

      Not For Intravascular Use

      Because inadvertent intravascular entry of HYPAQUE-CYSTO is possible during urethrocystography (bladder absorption or pyelorenal back flow), the occurrence of systemic adverse effects is possible. However, the relative incidence and severity of the following reactions refer only to experience with direct injection.

      Approximately 95 percent of adverse reactions accompanying the intravascular use of diatrizoate salts are of mild to moderate severity. However, life-threatening reactions and fatalities, mostly of cardiovascular origin, have occurred.

      Adverse reactions to injectable contrast media fall into two categories: chemotoxic reactions and idiosyncratic reactions.

      Chemotoxic reactions result from the physicochemical properties of the contrast media, the dose, and the speed of injection. All hemodynamic disturbances and injuries to organs or vessels perfused by the contrast medium are included in this category.

      Idiosyncratic reactions include all other reactions. They occur more frequently in patients 20 to 40 years old. Idiosyncratic reactions may or may not be dependent on the amount of dose injected, the speed of injection, the mode of injection, and the radiographic procedure. Idiosyncratic reactions are subdivided into minor, intermediate, and severe. The minor reactions are self-limited and of short duration; the severe reactions are life-threatening and treatment is urgent and mandatory.

      The reported incidence of adverse reactions to contrast media in patients with a history of allergy are twice that of the general population. Patients with a history of previous reactions to a contrast medium are three times more susceptible than other patients. However, sensitivity to contrast media does not appear to increase with repeated examinations.

      Most adverse reactions to injectable contrast media appear within one to three minutes after the start of injection, but delayed reactions may occur.

      Adverse reactions are grouped by organ system and listed below by decreasing order of occurrence and with an approximate incidence of occurrence. Significantly more severe reactions are listed before the other reactions regardless of frequency.




      What should I look out for while using HYPAQUE - CYSTO?

      HYPAQUE-CYSTO has no absolute contraindication in its recommended use.


      What might happen if I take too much HYPAQUE - CYSTO?

      Sorry No Records found


      How should I store and handle HYPAQUE - CYSTO?

      Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 20073 mL (100 mg/mL) ampules, box of 10 (NDC 11098-526-03).


      &times

      Clinical Information

      Chemical Structure

      No Image found
      Clinical Pharmacology

      HYPAQUE-CYSTO which gains inadvertent intravascular entry is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its cation moiety.

      Diatrizoate solutions may be excreted either through the kidneys or the liver. These two excretory pathways are not mutually exclusive, but the main route of excretion seems to be governed by the affinity of the contrast medium for serum albumin. From 0% to 10% of diatrizoate meglumine is bound to serum protein.

      Diatrizoate salts are excreted unchanged predominantly through the kidneys by glomerular filtration. The amount excreted during any period of time is determined by the filtered load; ie, the product of plasma contrast media concentration and glomerular filtration rate.

      The liver and small intestine provide the major alternate route of excretion for diatrizoate. In patients free of severe renal disease, the fecal recovery is less than 2 percent. In patients with severe renal impairment the excretion of these contrast media through the gallbladder and into the small intestine sharply increases; up to 20 percent in the feces in 48 hours.

      Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents. In patients with normal renal function, minimal amounts of contrast media are secreted unchanged.

      Non-Clinical Toxicology
      HYPAQUE-CYSTO has no absolute contraindication in its recommended use.

      Anticoagulants (oral)

      ß-adrenergic blocking agents

      Digitalis glycosides

      Theophylline

      Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for the management of any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. Competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions have occurred (See ).

      The possibility of a reaction, including serious, life-threatening, fatal, anaphylatic or cardiovascular reactions should always be considered (see ). It is of utmost importance that a course of action be carefully planned in advance for immediate treatment of serious reactions, and that adequate and appropriate personnel be readily available in case of any reaction.

      &times

      Reference

      This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
      "https://dailymed.nlm.nih.gov/dailymed/"

      While we update our database periodically, we cannot guarantee it is always updated to the latest version.

      &times

      Review

      Rate this treatment and share your opinion


      Helpful tips to write a good review:

      1. Only share your first hand experience as a consumer or a care giver.
      2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
      3. Fill in the optional information to help other users benefit from your review.

      Reason for Taking This Treatment

      (required)

      Click the stars to rate this treatment

      This medication has worked for me.




      This medication has been easy for me to use.




      Overall, I have been satisfied with my experience.




      Write a brief description of your experience with this treatment:

      2000 characters remaining

      Optional Information

      Help others benefit from your review by filling in the information below.
      I am a:
      Gender:
      &times

      Professional

      Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
      &times

      Tips

      Tips

      &times

      Interactions

      Interactions

      A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).